Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations

Yi Hsin Liang, Yu Lin Lin, Jau Yu Liau, Jia Huei Tsai, Jin Tung Liang, Been Ren Lin, Ji Shiang Hung, Li Hui Tseng, Liang In Lin, Yih Leong Chang, Ann Lii Cheng, Kun Huei Yeh

Research output: Contribution to journalArticle

Abstract

Background: Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear. Patients and Methods: This was a retrospective study enrolling 163 patients with unresectable KRAS-mutant mCRC diagnosed at the National Taiwan University Hospital between 2007 and 2011. Results: The median overall survival (mOS) was 29.5 months in patients who had never used cetuximab and 19.0 months in those who had (p=0.040). The mOS was 32.0 months in patients with mutant KRAS codon 12 who had never used cetuximab and 17.5 months in those who had (p=0.017). In patients with mutant KRAS codon 13, the mOS was not significantly different. Univariate and multivariate Cox proportional hazards analysis revealed that absence of cetuximab treatment was an independent prognostic factor for longer mOS in patients with unresectable KRAS-mutant mCRC. Conclusion: Cetuximab usage might be detrimental to patients with mCRC with mutant KRAS codon 12.

Original languageEnglish (US)
Pages (from-to)4207-4214
Number of pages8
JournalAnticancer Research
Volume35
Issue number7
StatePublished - Jul 1 2015
Externally publishedYes

Fingerprint

Codon
Colorectal Neoplasms
Mutation
Survival
Cetuximab
Taiwan
Epidermal Growth Factor Receptor
Exons
Retrospective Studies
Monoclonal Antibodies

Keywords

  • Cetuximab
  • Epidermal growth factor receptor
  • KRAS
  • Metastatic colorectal cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Liang, Y. H., Lin, Y. L., Liau, J. Y., Tsai, J. H., Liang, J. T., Lin, B. R., ... Yeh, K. H. (2015). Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations. Anticancer Research, 35(7), 4207-4214.

Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations. / Liang, Yi Hsin; Lin, Yu Lin; Liau, Jau Yu; Tsai, Jia Huei; Liang, Jin Tung; Lin, Been Ren; Hung, Ji Shiang; Tseng, Li Hui; Lin, Liang In; Chang, Yih Leong; Cheng, Ann Lii; Yeh, Kun Huei.

In: Anticancer Research, Vol. 35, No. 7, 01.07.2015, p. 4207-4214.

Research output: Contribution to journalArticle

Liang, YH, Lin, YL, Liau, JY, Tsai, JH, Liang, JT, Lin, BR, Hung, JS, Tseng, LH, Lin, LI, Chang, YL, Cheng, AL & Yeh, KH 2015, 'Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations', Anticancer Research, vol. 35, no. 7, pp. 4207-4214.
Liang YH, Lin YL, Liau JY, Tsai JH, Liang JT, Lin BR et al. Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations. Anticancer Research. 2015 Jul 1;35(7):4207-4214.
Liang, Yi Hsin ; Lin, Yu Lin ; Liau, Jau Yu ; Tsai, Jia Huei ; Liang, Jin Tung ; Lin, Been Ren ; Hung, Ji Shiang ; Tseng, Li Hui ; Lin, Liang In ; Chang, Yih Leong ; Cheng, Ann Lii ; Yeh, Kun Huei. / Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations. In: Anticancer Research. 2015 ; Vol. 35, No. 7. pp. 4207-4214.
@article{9356d9da74c4414ba2f21c6f683ab323,
title = "Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations",
abstract = "Background: Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear. Patients and Methods: This was a retrospective study enrolling 163 patients with unresectable KRAS-mutant mCRC diagnosed at the National Taiwan University Hospital between 2007 and 2011. Results: The median overall survival (mOS) was 29.5 months in patients who had never used cetuximab and 19.0 months in those who had (p=0.040). The mOS was 32.0 months in patients with mutant KRAS codon 12 who had never used cetuximab and 17.5 months in those who had (p=0.017). In patients with mutant KRAS codon 13, the mOS was not significantly different. Univariate and multivariate Cox proportional hazards analysis revealed that absence of cetuximab treatment was an independent prognostic factor for longer mOS in patients with unresectable KRAS-mutant mCRC. Conclusion: Cetuximab usage might be detrimental to patients with mCRC with mutant KRAS codon 12.",
keywords = "Cetuximab, Epidermal growth factor receptor, KRAS, Metastatic colorectal cancer",
author = "Liang, {Yi Hsin} and Lin, {Yu Lin} and Liau, {Jau Yu} and Tsai, {Jia Huei} and Liang, {Jin Tung} and Lin, {Been Ren} and Hung, {Ji Shiang} and Tseng, {Li Hui} and Lin, {Liang In} and Chang, {Yih Leong} and Cheng, {Ann Lii} and Yeh, {Kun Huei}",
year = "2015",
month = "7",
day = "1",
language = "English (US)",
volume = "35",
pages = "4207--4214",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations

AU - Liang, Yi Hsin

AU - Lin, Yu Lin

AU - Liau, Jau Yu

AU - Tsai, Jia Huei

AU - Liang, Jin Tung

AU - Lin, Been Ren

AU - Hung, Ji Shiang

AU - Tseng, Li Hui

AU - Lin, Liang In

AU - Chang, Yih Leong

AU - Cheng, Ann Lii

AU - Yeh, Kun Huei

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background: Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear. Patients and Methods: This was a retrospective study enrolling 163 patients with unresectable KRAS-mutant mCRC diagnosed at the National Taiwan University Hospital between 2007 and 2011. Results: The median overall survival (mOS) was 29.5 months in patients who had never used cetuximab and 19.0 months in those who had (p=0.040). The mOS was 32.0 months in patients with mutant KRAS codon 12 who had never used cetuximab and 17.5 months in those who had (p=0.017). In patients with mutant KRAS codon 13, the mOS was not significantly different. Univariate and multivariate Cox proportional hazards analysis revealed that absence of cetuximab treatment was an independent prognostic factor for longer mOS in patients with unresectable KRAS-mutant mCRC. Conclusion: Cetuximab usage might be detrimental to patients with mCRC with mutant KRAS codon 12.

AB - Background: Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear. Patients and Methods: This was a retrospective study enrolling 163 patients with unresectable KRAS-mutant mCRC diagnosed at the National Taiwan University Hospital between 2007 and 2011. Results: The median overall survival (mOS) was 29.5 months in patients who had never used cetuximab and 19.0 months in those who had (p=0.040). The mOS was 32.0 months in patients with mutant KRAS codon 12 who had never used cetuximab and 17.5 months in those who had (p=0.017). In patients with mutant KRAS codon 13, the mOS was not significantly different. Univariate and multivariate Cox proportional hazards analysis revealed that absence of cetuximab treatment was an independent prognostic factor for longer mOS in patients with unresectable KRAS-mutant mCRC. Conclusion: Cetuximab usage might be detrimental to patients with mCRC with mutant KRAS codon 12.

KW - Cetuximab

KW - Epidermal growth factor receptor

KW - KRAS

KW - Metastatic colorectal cancer

UR - http://www.scopus.com/inward/record.url?scp=84937110854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937110854&partnerID=8YFLogxK

M3 - Article

C2 - 26124380

AN - SCOPUS:84937110854

VL - 35

SP - 4207

EP - 4214

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -